Literature DB >> 15888346

Novel p38 MAP kinase inhibitor R-130823 suppresses IL-6, IL-8 and MMP-13 production in spheroid culture of human synovial sarcoma cell line SW 982.

Yoshihiro Wada1, Kohei Shimada, Tomio Kimura, Shigeru Ushiyama.   

Abstract

Synovial hyperplasia is a hallmark of rheumatoid arthritis (RA) and is regarded as a major destructive element of articular bone and cartilage. This pathological process is accompanied by the production of proinflammatory cytokines, prostaglandin E(2) (PGE(2)), and matrix metalloproteinases (MMPs) in synoviocytes. We studied the spontaneous production of these substances in RA synoviocytes in spheroid culture. Synovial sarcoma cell line SW 982 formed a single spheroid in non-adherent culture plates. It produced interleukin (IL)-1beta, IL-6, IL-8, PGE(2), MMP-2 and MMP-13. Neither the addition of integrin antagonizing oligopeptide (GRGDSP) nor that of vitronectin receptor inhibitor SB-265123 to the culture inhibited any production. Phosphorylation of p38 mitogen-activated protein (MAP) kinase was observed during the culture. A novel p38 MAP kinase inhibitor, R-130823, inhibited the release of IL-6, IL-8 and MMP-13 in a concentration-dependent manner, but not that of IL-1beta or MMP-2. Real-time RT-PCR analysis demonstrated that IL-6, IL-8 and MMP-13 were inhibited at the transcriptional level. R-130823 did not affect the production of PGE(2) in spheroid culture, while the addition of R-130823 suppressed IL-1beta-induced PGE(2) synthesis in monolayer culture of SW 982 cells. The results suggest that spheroid culture induced proinflammatory factors and MMPs in signaling pathways both dependent and independent of p38 MAP kinase.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15888346     DOI: 10.1016/j.imlet.2005.04.010

Source DB:  PubMed          Journal:  Immunol Lett        ISSN: 0165-2478            Impact factor:   3.685


  5 in total

Review 1.  p38(MAPK): stress responses from molecular mechanisms to therapeutics.

Authors:  Lydia R Coulthard; Danielle E White; Dominic L Jones; Michael F McDermott; Susan A Burchill
Journal:  Trends Mol Med       Date:  2009-08-06       Impact factor: 11.951

Review 2.  Toll gates to periodontal host modulation and vaccine therapy.

Authors:  George Hajishengallis
Journal:  Periodontol 2000       Date:  2009       Impact factor: 7.589

3.  In vitro efficacy of polysaccharide-based nanoparticles containing disease-modifying antirheumatic drugs.

Authors:  Nan Zhang; Patricia R Wardwell; Rebecca A Bader
Journal:  Pharm Res       Date:  2014-03-05       Impact factor: 4.200

4.  The resistance of intracellular mediators to doxorubicin and cisplatin are distinct in 3D and 2D endometrial cancer.

Authors:  Kenny Chitcholtan; Peter H Sykes; John J Evans
Journal:  J Transl Med       Date:  2012-03-06       Impact factor: 5.531

5.  Tofacitinib Inhibits STAT Phosphorylation and Matrix Metalloproteinase-3, -9 and -13 Production by C28/I2 Human Juvenile Chondrocytes.

Authors:  Jessica R Thorpe; Rachel A Wilson; Sam Mesiano; Charles J Malemud
Journal:  Open Access Rheumatol       Date:  2022-10-04
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.